RCUS
Arcus Biosciences, Inc.
NYSE · Healthcare · Biotechnology · US
$25.24
−1.17%Next report
Analyst consensus
- Next report date
- Oct 27, 2026
- EPS estimate
- -$0.94
- Revenue estimate
- $11.0M
Latest reported
- Last report date
- Aug 5, 2026
- EPS actual
- -$0.72
- EPS estimate
- -$0.89
- Revenue actual
- $41.0M
- Revenue estimate
- $22.0M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 1
- EPS in line (12Q)
- 3
- Avg surprise (4Q)
- +8.2%
- Revenue beats (12Q)
- 9
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $39
- PT range
- $26 – $45
- Analysts
- 5
4 Buy1 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 5, 2026 | -$0.89 | -$0.72 | Beat 19.21% | $41.0M |
| May 5, 2026 | -$0.92 | -$1.02 | Miss -10.87% | $17.0M |
| Feb 25, 2026 | -$1.11 | -$0.89 | Beat 19.82% | $33.0M |
| Oct 28, 2025 | -$1.33 | -$1.27 | Beat 4.51% | $26.0M |
| Aug 6, 2025 | -$1.14 | -$0.08 | Beat 93.41% | $160.0M |
| Feb 25, 2025 | -$1.17 | -$1.03 | Beat 11.97% | $26.0M |
| Aug 8, 2024 | -$1.02 | -$1.02 | In line | $39.0M |
| May 8, 2024 | -$0.97 | -$0.05 | Beat 94.85% | $145.0M |
| Feb 21, 2024 | -$1.09 | -$1.08 | Beat 0.92% | $31.0M |
| Feb 28, 2023 | -$0.99 | -$0.93 | Beat 6.06% | — |
| Nov 2, 2022 | -$1.05 | -$0.90 | Beat 14.29% | $33.6M |
| Aug 3, 2022 | -$0.93 | -$0.93 | In line | $26.8M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Oct 27, 2026